Related Experiment Video

Updated: Apr 27, 2026

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

19.7K

[Effect of multimodality therapies on plasma soluble tumor necrosis factor receptor I in OSAHS patients]

Xiaohui Feng, Fei Zhou, Jihua Wang

    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Journal of Clinical Otorhinolaryngology Head and Neck Surgery
    |June 26, 2014
    PubMed
    Abstract

    Insights

    Soluble TNF receptor-I levels are elevated in obstructive sleep apnea hypopnea syndrome (OSAHS) and correlate with disease severity. Comprehensive therapies effectively reduce these levels, suggesting sTNF-R I as a potential inflammation marker for OSAHS.

    Area of Science:

    • Immunology
    • Sleep Medicine
    • Respiratory Medicine

    Background:

    • Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) is a prevalent condition linked to inflammation.
    • The role of soluble TNF receptor-I (sTNF-R I), a subtype of tumor necrosis factor alpha receptor, in OSAHS is not well understood.
    • This study investigates the association between sTNF-R I and OSAHS severity and the impact of treatments on its levels.

    Purpose of the Study:

    • To examine the relationship between serum sTNF-R I levels and OSAHS severity.
    • To evaluate the effect of multimodality therapies (ENT surgery or CPAP) on peripheral blood sTNF-R I levels in OSAHS patients.
    • To determine if sTNF-R I can serve as an inflammation marker for OSAHS.

    Main Methods:

    • Seventy-seven adult participants with habitual snoring underwent polysomnography, physical examination, and blood tests.
    • Participants were categorized into moderate/severe OSAHS groups and a control group.
    • sTNF-R I serum levels were measured using an immunoluminometric assay before and after 3 months of treatment (ENT surgery or CPAP) for moderate/severe OSAHS groups.

    Main Results:

    • Serum sTNF-R I levels were significantly higher in OSAHS groups compared to the control group (P < 0.05).
    • Apnea-Hypopnea Index (AHI) showed a positive association with sTNF-R I (r = 0.646, P < 0.01), while lowest nadir oxygen saturation (LSaO2) showed a negative association (r = 0.522, P < 0.01).
    • Comprehensive therapies led to a significant reduction in plasma sTNF-R I levels post-treatment.

    Conclusions:

    • Elevated serum sTNF-R I levels are associated with OSAHS severity, independent of age, gender, BMI, and weight.
    • Multimodality therapies effectively modulate peripheral blood sTNF-R I levels in OSAHS patients.
    • sTNF-R I may serve as a valuable inflammation biomarker for obstructive sleep apnea hypopnea syndrome.

    More Related Videos

    Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia04:59

    Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

    Published on: May 30, 2025

    2.2K
    Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD &#8212; A Safe, Cost-Effective Approach04:53

    Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

    Published on: October 18, 2024

    1.6K

    Related Concept Videos

    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    631
    Sleep Apnea01:21

    Sleep Apnea

    Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
    The condition is more prevalent among...
    909
    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

    Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

    Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
    Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
    815
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
    611